ClinicalTrials.gg
TerminatedNCT01919606Updated Mar 2, 2021Results posted

EXPAREL Administered Into the TAP for Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy

A Phase 4 interventional study of EXPAREL in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Terminated. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-02.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Why this study was terminated
Lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Enrollment
88th of 93
1 · median 80
Started
2012
with 5 others
Phase 4
52 of 93
5 open now
Registered
3rd of 93
by date
Lead sponsor
11 of 93
Pacira Pharmaceuticals, Inc

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 88th largest by enrollment, is one of 6 that started in 2012, is one of 52 in phase 4, and was the 3rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the optimal of two different volumes of EXPAREL 266 mg when administered via infiltration into the transversus abdominis plane (TAP) for prolonged postoperative analgesia in subjects undergoing open total abdominal hysterectomy.

Read the detailed description

This is a prospective, open-label, non-randomized study with two treatment groups differing only in the volume of EXPAREL infiltrated into the TAP. All subjects will undergo an open total abdominal hysterectomy. The dose of EXPAREL for the TAPs will be the same for all 20 subjects, 133 mg on the right side of the abdomen and 133 mg on the left side of the abdomen.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • hysterectomy
  • analgesia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females, 18-75 years of age inclusive.
  • (ASA) physical status 1-3.
  • Undergoing open total abdominal hysterectomy (i.e., laparoscopic procedures are not sufficient) without any concurrent surgical procedure(s).
  • Physically and mentally able to participate in the study and complete all study assessments.
  • Able to give fully to participate in this study after demonstrating a good understanding of the risks and benefits of the TAP.

Exclusion criteria

Exclusion Criteria:

  • Demonstrated or idiosyncratic reactions to amide-type local anesthetics.
  • Any subject whose anatomy, or surgical procedure, in the opinion of the Investigator, might preclude the potential successful performance of a TAP.
  • Any subject who in the opinion of the Investigator might be harmed or be a poor candidate for participation in the study.
  • Any subject, who in the opinion of the Investigator, is on chronic pain medicine.
  • Subjects who have received any drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during their participation in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    EXPAREL Group 1

    EXPAREL 266 mg diluted with saline to a volume of 40 mL

    Drug: EXPAREL

  • Experimental
    EXPAREL Group 2

    EXPAREL 266 mg diluted with saline to a volume of 60 mL

    Drug: EXPAREL

Interventions

  • Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.

    Also known as: Bupivacaine liposome injectable suspension

06

What researchers measure

Primary outcomes

  1. Duration of Analgesia

    Time frame: End of surgery to time of subject's first postsurgical opioid administration (through 72 hours)

Secondary outcomes

  1. Incidence of Adverse Events

    Time frame: 10 days post surgery plus or minus 3 days

07

Results

Posted May 14, 2014

Participant flow

Participant flow — Overall Study
MilestoneEXPAREL Group 1EXPAREL Group 2
Started10
Completed10
Not completed00

Outcome measures

PrimaryDuration of Analgesia
Time frame:
End of surgery to time of subject's first postsurgical opioid administration (through 72 hours)

No measurements were reported for this outcome.

SecondaryIncidence of Adverse Events
Time frame:
10 days post surgery plus or minus 3 days
Reported as:
Number · number of events
Incidence of Adverse Events
number of eventsEXPAREL Group 1EXPAREL Group 2
Incidence of Adverse Events0—

Adverse events

Collected over 10 days post surgery plus or minus 3 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL Group 1—0/1 (0%)0/1 (0%)
EXPAREL Group 2———

Baseline characteristics

Age, Continuous
Age, Continuous(years)EXPAREL Group 1EXPAREL Group 2Total
Mean67 ± 0—67 ± 0
Age, Categorical
Age, Categorical(Participants)EXPAREL Group 1EXPAREL Group 2Total
<=18 years0—0
Between 18 and 65 years0—0
>=65 years1—1
Sex: Female, Male
Sex: Female, Male(Participants)EXPAREL Group 1EXPAREL Group 2Total
Female1—1
Male0—0
Region of Enrollment
Region of Enrollment(participants)EXPAREL Group 1EXPAREL Group 2Total
United States1—1
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2013
First posted
Aug 9, 2013
Start
Aug 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
May 14, 2014
Last update
Mar 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01919606
Responsible party
Sponsor
First posted
Aug 9, 2013
Start date
Aug 2012
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
May 14, 2014
Last update
Mar 2, 2021

Study contacts

Robert Dorian, MD
principal investigator · St. Barnabas Medical Center, Livingston, NJ 07039
Thad Denehy, MD
principal investigator · St. Barnabas Medical Center, Livingston, NJ 07039

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion